Published in World J Surg on September 29, 2004
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther (2010) 1.21
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol (2011) 1.14
The role of radiation therapy in pancreas cancer. Gastrointest Cancer Res (2009) 0.99
Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation. Oncotarget (2014) 0.95
Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer (2008) 0.87
Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Gastrointest Cancer Res (2011) 0.81
Adenosquamous carcinoma of the pancreas, a rare tumor entity: a case report. Cases J (2009) 0.80
Robotic radiosurgery in pancreatic cancer: A systematic review. World J Gastroenterol (2015) 0.77
Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta (2017) 0.75
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Cancer statistics, 1996. CA Cancer J Clin (1996) 6.85
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst (1988) 2.95
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol (1997) 2.75
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs (1994) 2.33
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol (1999) 2.19
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2001) 2.18
Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys (1996) 2.11
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol (2001) 2.01
Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res (1996) 1.74
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil. Clin Oncol (R Coll Radiol) (2002) 1.44
Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer (2000) 1.26
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg (1993) 1.19
Preoperative irradiation in carcinoma of the pancreas. Cancer (1980) 1.18
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer (2002) 1.09
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol (2001) 1.03
A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer (2002) 1.00
Pancreatic carcinoma. Ann Oncol (1995) 0.96
Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys (2003) 0.94
Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys (1999) 0.89
Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol (2002) 0.88
Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2003) 0.87
Adjuvant and neoadjuvant radiochemotherapy in ductal pancreatic carcinoma. Strahlenther Onkol (2000) 0.76
[The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine]. Strahlenther Onkol (1999) 0.76
Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study. Tumori (2002) 0.75
Perspective: Evolution and detection of genetic robustness. Evolution (2003) 4.10
Robustness can evolve gradually in complex regulatory gene networks with varying topology. PLoS Comput Biol (2007) 3.09
Cryptic genetic variation promotes rapid evolutionary adaptation in an RNA enzyme. Nature (2011) 2.63
Asymmetric sequence divergence of duplicate genes. Genome Res (2003) 2.28
Neutralism and selectionism: a network-based reconciliation. Nat Rev Genet (2008) 2.15
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs (2007) 2.08
Structure and evolution of protein interaction networks: a statistical model for link dynamics and gene duplications. BMC Evol Biol (2004) 2.01
Duplicate genes and robustness to transient gene knock-downs in Caenorhabditis elegans. Proc Biol Sci (2004) 1.94
Convergent evolution of gene circuits. Nat Genet (2003) 1.89
Influence of metabolic network structure and function on enzyme evolution. Genome Biol (2006) 1.79
The robustness and evolvability of transcription factor binding sites. Science (2014) 1.76
Growth temperature and genome size in bacteria are negatively correlated, suggesting genomic streamlining during thermal adaptation. Genome Biol Evol (2013) 1.59
Cholangiocarcinoma. Crit Rev Oncol Hematol (2008) 1.59
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology (2006) 1.58
Molecular evolution in large genetic networks: does connectivity equal constraint? J Mol Evol (2004) 1.55
Interventional therapy of bifurcation lesions: a TIMI flow-guided concept to treat side branches in bifurcation lesions--a prospective randomized clinical study (Thueringer bifurcation study, THUEBIS study as pilot trial). Circ Cardiovasc Interv (2009) 1.52
Severe accidental hypothermia with or without hemodynamic instability: rewarming without the use of extracorporeal circulation. Wien Klin Wochenschr (2002) 1.52
Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie (2007) 1.51
Evolutionary plasticity and innovations in complex metabolic reaction networks. PLoS Comput Biol (2009) 1.43
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie (2007) 1.42
Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels. Anticancer Drugs (2013) 1.42
Export aspiration system in patients with acute coronary syndrome and visible thrombus provides no substantial benefit. Catheter Cardiovasc Interv (2007) 1.39
A latent capacity for evolutionary innovation through exaptation in metabolic systems. Nature (2013) 1.38
A model of protein translation including codon bias, nonsense errors, and ribosome recycling. J Theor Biol (2005) 1.32
Effects of a computer-based nursing documentation system on the quality of nursing documentation. J Med Syst (2007) 1.31
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci (2013) 1.31
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol (2013) 1.30
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
A statistical framework for combining and interpreting proteomic datasets. Bioinformatics (2004) 1.28
Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol (2005) 1.27
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP (2006) 1.27
Specialization can drive the evolution of modularity. PLoS Comput Biol (2010) 1.27
Efficient characterization of high-dimensional parameter spaces for systems biology. BMC Syst Biol (2011) 1.26
GenomeHistory: a software tool and its application to fully sequenced genomes. Nucleic Acids Res (2002) 1.25
Influence of prebiotics and antioxidants in bread on the immune system, antioxidative status and antioxidative capacity in male smokers and non-smokers. Br J Nutr (2007) 1.24
Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol (2007) 1.23
Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci (2008) 1.23
Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist (2008) 1.19
Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl (2004) 1.18
New structural variation in evolutionary searches of RNA neutral networks. Biosystems (2006) 1.17
Protein robustness promotes evolutionary innovations on large evolutionary time-scales. Proc Biol Sci (2008) 1.16
Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery (2010) 1.15
X-ray detection of structural orientation in human articular cartilage. Osteoarthritis Cartilage (2004) 1.15
Ductal pancreatic adenocarcinoma. Dtsch Arztebl Int (2014) 1.14
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie (2005) 1.14
High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol (2013) 1.13
Genotype networks in metabolic reaction spaces. BMC Syst Biol (2010) 1.12
Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev (2008) 1.10
Phenotypic plasticity can facilitate adaptive evolution in gene regulatory circuits. BMC Evol Biol (2011) 1.09
A comparison of genotype-phenotype maps for RNA and proteins. Biophys J (2012) 1.09
Evolution of viral proteins originated de novo by overprinting. Mol Biol Evol (2012) 1.09
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer (2009) 1.08
The Systems Biology Research Tool: evolvable open-source software. BMC Syst Biol (2008) 1.08
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs (2008) 1.08
Batch and continuous culture-based selection strategies for acetic acid tolerance in xylose-fermenting Saccharomyces cerevisiae. FEMS Yeast Res (2011) 1.07
The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. Dtsch Arztebl Int (2009) 1.07
Risk of advanced colorectal neoplasia according to age and gender. PLoS One (2011) 1.05
Evolutionary innovations and the organization of protein functions in genotype space. PLoS One (2010) 1.05
Neutral network sizes of biological RNA molecules can be computed and are not atypically small. BMC Bioinformatics (2008) 1.05
'Glocal' robustness analysis and model discrimination for circadian oscillators. PLoS Comput Biol (2009) 1.05
Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res (2012) 1.04
Superessential reactions in metabolic networks. Proc Natl Acad Sci U S A (2012) 1.02
Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer (2013) 1.02
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol (2010) 1.02
The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology (2008) 1.01
Hsp90 is important for fecundity, longevity, and buffering of cryptic deleterious variation in wild fly populations. BMC Evol Biol (2012) 1.01
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol (2012) 1.01
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP (2006) 1.00
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology (2008) 1.00
Automatic generation of predictive dynamic models reveals nuclear phosphorylation as the key Msn2 control mechanism. Sci Signal (2013) 1.00
18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med (2012) 0.99
Direct time-of-flight for quantitative, real-time in-beam PET: a concept and feasibility study. Phys Med Biol (2007) 0.99
Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J Biol Chem (2004) 0.99
Range assessment in particle therapy based on prompt γ-ray timing measurements. Phys Med Biol (2014) 0.99
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs (2011) 0.98
Pervasive indels and their evolutionary dynamics after the fish-specific genome duplication. Mol Biol Evol (2012) 0.98
Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol (2008) 0.98
Beneficial effects of ischemic preconditioning in patients undergoing hepatectomy: the role of neutrophils. Arch Surg (2005) 0.98
Protein material costs: single atoms can make an evolutionary difference. Trends Genet (2008) 0.98
Effects of recombination on complex regulatory circuits. Genetics (2009) 0.97
Risk factors for surgical complications in distal pancreatectomy. Am J Surg (2010) 0.96
Molecular evolution in the yeast transcriptional regulation network. J Exp Zool B Mol Dev Evol (2004) 0.96
Exhaustive identification of steady state cycles in large stoichiometric networks. BMC Syst Biol (2008) 0.96
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res (2010) 0.96
Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med (2013) 0.96
Protein carbon content evolves in response to carbon availability and may influence the fate of duplicated genes. Proc Biol Sci (2007) 0.95
Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis. Arthritis Res Ther (2005) 0.94
Evolvability and robustness in a complex signalling circuit. Mol Biosyst (2011) 0.94
Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. Transpl Int (2003) 0.94
Genotype networks, innovation, and robustness in sulfur metabolism. BMC Syst Biol (2011) 0.94
Multifunctionality and robustness trade-offs in model genetic circuits. Biophys J (2008) 0.93
Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol (2003) 0.93
Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol (2003) 0.93
Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol (2007) 0.93